Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
February 04 2022 - 9:40AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a‑16 OR 15d‑16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
FOR THE MONTH OF FEBRUARY 2022
COMMISSION FILE NUMBER 001-34041
|
Evotec SE
|
|
(Translation of registrant’s name into English)
|
Essener Bogen 7
22419 Hamburg
Germany
Tel: +49 40 560810
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover Form 20‑F or Form 40‑F: Form 20‑F ☒ Form 40‑F ☐
Indicate by check mark if the registrant is submitting the Form 6‑K in paper as permitted by Regulation S‑T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting the Form 6‑K in paper as permitted by Regulation S‑T Rule 101(b)(7): ☐
On February 4, 2022, Evotec SE (the “Company”) announced that the Company has been informed by Bayer about a decision to discontinue the development of the investigational P2X3 receptor antagonist eliapixant (BAY1817080), which stems from a former Evotec/Bayer multi-target research alliance. The ad hoc release is attached hereto as Exhibit 99.1.
SIGNATURE
Pursuant to the requirements of s the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
|
Evotec SE
|
|
|
|
|
|
|
|
Date: February 4, 2022
|
By:
|
/s/Enno Spillner
|
|
|
|
|
Name: Enno Spillner
|
|
|
|
|
Title: Chief Financial Officer
|
|
EXHIBIT INDEX
Evotec (NASDAQ:EVO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Evotec (NASDAQ:EVO)
Historical Stock Chart
From Apr 2023 to Apr 2024
